Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
George N. Ioannou, MD, MS
Professor & Director of Hepatology,
VA Puget Sound Health Care System

Dr. Ioannou is a professor based at the VA Puget Sound Health Care System. He specializes in hepatitis C, non-alcoholic fatty liver disease, iron deficiency and iron overload.

Recent Publications
Displaying 20 Most Recent Publications from PubMed

February 2019. Reply. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. Gastroenterology. 2019 Feb 19. pii: S0016-5085(19)30398-1. doi: 10.1053/j.gastro.2019.02.024. [Epub ahead of print]

February 2019. For Whom is Hepatocellular Carcinoma Surveillance after Sustained Virologic Response Cost Effective? Singal AG, Ioannou GN. Clin Gastroenterol Hepatol. 2019 Feb 14. pii: S1542-3565(19)30183-1. doi: 10.1016/j.cgh.2019.02.020. [Epub ahead of print]

January 2019. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence after Liver Transplantation: The RH-IML Classification. Vutien P, Dodge J, Bambha KM, Nordstrom EM, Gralla J, Campbell K, Levek C, Nydam T, Fix O, Ioannou G, Biggins SW. Liver Transpl. 2019 Jan 31. doi: 10.1002/lt.25422. [Epub ahead of print]

January 2019. Machine learning models to predict disease progression among veterans with hepatitis C virus. Konerman MA, Beste LA, Van T, Liu B, Zhang X, Zhu J, Saini SD, Su GL, Nallamothu BK, Ioannou GN, Waljee AK. PLoS One. 2019 Jan 4;14(1):e0208141. doi: 10.1371/journal.pone.0208141. eCollection 2019.

December 2018. The impact of direct-acting antiviral therapy for hepatitis C on hepatocellular carcinoma risk. Su F, Ioannou GN. Curr Hepatol Rep. 2018 Dec;17(4):377-384. doi: 10.1007/s11901-018-0424-8. Epub 2018 Sep 20.

October 2018. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling. Liang JQ, Teoh N, Xu L, Pok S, Li X, Chu ESH, Chiu J, Dong L, Arfianti E, Haigh WG, Yeh MM, Ioannou GN, Sung JJY, Farrell G, Yu J. Nat Commun. 2018 Oct 26;9(1):4490. doi: 10.1038/s41467-018-06931-6.

October 2018. What are the Benefits of a Sustained Virologic Response to Direct-acting Antiviral Therapy for HCV Infection? Ioannou GN, Feld JJ. Gastroenterology. 2018 Oct 24. pii: S0016-5085(18)35166-7. doi: 10.1053/j.gastro.2018.10.033. [Epub ahead of print]

October 2018. Reply to: "Individual surveillance using model-based hepatocellular carcinoma risk estimates in chronic hepatitis C patients after antiviral treatment". Ioannou GN. J Hepatol. 2018 Oct 19. pii: S0168-8278(18)32445-0. doi: 10.1016/j.jhep.2018.09.026. [Epub ahead of print]

September 2018. Differences in hepatocellular carcinoma risk, predictors and trends over time according to etiology of cirrhosis. Ioannou GN, Green P, Lowy E, Mun EJ, Berry K. PLoS One. 2018 Sep 27;13(9):e0204412. doi: 10.1371/journal.pone.0204412. eCollection 2018.

August 2018. No difference between direct-acting antivirals for hepatitis C in hepatocellular carcinoma risk. Mun EJ, Green P, Berry K, Ioannou GN. Eur J Gastroenterol Hepatol. 2018 Aug 23. doi: 10.1097/MEG.0000000000001242. [Epub ahead of print]

August 2018. Development of Models Estimating the Risk of Hepatocellular Carcinoma After Antiviral Treatment for Hepatitis C. Ioannou GN, Green PK, Beste LA, Mun EJ, Kerr KF, Berry K. J Hepatol. 2018 Aug 20. pii: S0168-8278(18)32287-6. doi: 10.1016/j.jhep.2018.07.024. [Epub ahead of print]

July 2018. No Association Between Screening for Hepatocellular Carcinoma and Reduced Cancer-related Mortality in Patients with Cirrhosis. Moon AM, Weiss NS, Beste LA, Su F, Ho SB, Jin GY, Lowy E, Berry K, Ioannou GN. Gastroenterology. 2018 Jul 5. pii: S0016-5085(18)34721-8. doi: 10.1053/j.gastro.2018.06.079. [Epub ahead of print]

May 2018. Receipt of alcohol-related care among patients with HCV and unhealthy alcohol use. Owens MD, Ioannou GN, Tsui JL, Edelman JE, Greene PA, Williams EC. Drug Alcohol Depend. 2018 May 8;188:79-85. doi: 10.1016/j.drugalcdep.2018.03.047. [Epub ahead of print]

February 2018. Mouse Models Of Nonalcoholic Steatohepatitis: A Reflection On Recent Literature. Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, Yu J, Teoh NC, Farrell GC. J Gastroenterol Hepatol. 2018 Feb 9. doi: 10.1111/jgh.14122. [Epub ahead of print]

December 2017. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid. Yoo W, Gjuka D, Stevenson HL, Song X, Shen H, Yoo SY, Wang J, Fallon M, Ioannou GN, Harrison SA, Beretta L. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017.

November 2017. Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C. Johnson K, Green PK, Ioannou GN. J Viral Hepat. 2017 Nov;24(11):966-975. doi: 10.1111/jvh.12731. Epub 2017 Jul 12.

October 2017. Genetic ablation of Cyp8b1 preserves host metabolic function by repressing steatohepatitis and altering gut microbiota composition. Patankar JV, Wong CK, Morampudi V, Gibson WT, Vallance B, Ioannou GN, Hayden M. Am J Physiol Endocrinol Metab. 2017 Oct 24:ajpendo.00172.2017. doi: 10.1152/ajpendo.00172.2017.

September 2017. Reply to Letters to the Editor Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. J Hepatol. 2017 Sep 19. pii: S0168-8278(17)32292-4. doi: 10.1016/j.jhep.2017.09.011. [Epub ahead of print]

September 2017. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. Ioannou GN, Green PK, Berry K. J Hepatol. 2017 Sep 5. pii: S0168-8278(17)32273-0. doi: 10.1016/j.jhep.2017.08.030. [Epub ahead of print]

September 2017. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Diabetes Care. 2017 Sep;40(9):1173-1180. doi: 10.2337/dc17-0485. Epub 2017 Jun 28.

July 2017. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Haczeyni F, Wang H, Barn V, Mridha AR, Yeh MM, Haigh WG, Ioannou GN, Choi YJ, McWherter CA, Teoh NC, Farrell GC. Hepatol Commun. 2017 Jul 31;1(7):663-674. doi: 10.1002/hep4.1072. eCollection 2017 Sep.

July 2017. TLR9 is upregulated in human and murine NASH: pivotal role for inflammatory recruitment and cell survival. Mridha AR, Haczeyni F, Yeh MM, Haigh WG, Ioannou GN, Barn V, Ajamieh H, Adams L, Hamdorf JM, Teoh NC, Farrell GC. Clin Sci (Lond). 2017 Jul 24;131(16):2145-2159. doi: 10.1042/CS20160838. Print 2017 Aug 15.

July 2017. Disparities in waitlist and posttransplantation outcomes in liver transplant registrants and recipients 18-24 years old: analysis of the UNOS database. Ebel NH, Hsu EK, Berry K, Horslen SP, Ioannou GN. Transplantation. 2017 Jul;101(7):1616-1627. doi: 10.1097/TP.0000000000001689.

July 2017. Effectiveness of hepatitis c antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma. Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. J Hepatol. 2017 Jul;67(1):32-39. doi: 10.1016/j.jhep.2017.02.027. Epub 2017 Mar 4.

June 2017. Reply to: Race or Genetic Makeup for HCV Treatment Decisions? Su F, Ioannou GN. Hepatology. 2017 Jun;65(6):2125-2126. doi: 10.1002/hep.29058. Epub 2017 Apr 24.

June 2017. Direct-acting antivirals are effective for chronic hepatitis C treatment in elderly patients: a real-world study of 17 487 patients. Su F, Beste LA, Green PK, Berry K, Ioannou GN. Eur J Gastroenterol Hepatol. 2017 Jun;29(6):686-693. doi: 10.1097/MEG.0000000000000858.

June 2017. Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH. Ioannou GN, Subramanian S, Chait A, Haigh WG, Yeh MM, Farrell GC, Lee SP, Savard C. J Lipid Res. 2017 Jun;58(6):1067-1079. doi: 10.1194/jlr.M072454. Epub 2017 Apr 12.

May 2017. Transplant-Related Survival Benefit Should Influence Prioritization for Liver Transplantation Especially in Patients with Hepatocellular Carcinoma. Ioannou GN. Liver Transpl. 2017 May;23(5):652-662. doi: 10.1002/lt.24690.

May 2017. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. Mridha AR, Wree A, Robertson AA, Yeh MM, Johnson CD, Van Rooyen DM, Haczeyni F, Teoh NC, Savard C, Ioannou GN, Masters SL, Schroder K, Cooper MA, Feldstein AE, Farrell GC. J Hepatol. 2017 May;66(5):1037-1046. doi: 10.1016/j.jhep.2017.01.022. Epub 2017 Feb 3.

February 2017. The association between race/ethnicity and the effectiveness of direct antiviral agents for hepatitis C virus infection. Su F, Green PK, Berry K, Ioannou GN. Hepatology. 2017 Feb;65(2):426-438. doi: 10.1002/hep.28901. Epub 2016 Dec 24.

Contact Info

M.D., Oxford University, Oxford, UK

Internship, Duke University, Durham, NC

Residency, Duke University, Durham, NC

FAASLD, American Association for the Study of Liver Diseases

©2016-2018 University of Washington Division of Gastroenterology
1959 NE Pacific St., Box 356424, Seattle, WA 98195-6424
Contact Us | Privacy | Terms | Copyright & Disclaimer